Osteochondrodysplasias clinical trials
The registry lists 18 studies for Osteochondrodysplasias across more than 10 countries. 6 are recruiting or about to start. 2 of them are mainly about Osteochondrodysplasias (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26. Counting its 6 narrower conditions too, such as Osteogenesis Imperfecta: 209 studies, 48 open.
Get an email when these change. Save the Osteochondrodysplasias studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
QED Therapeutics, a BridgeBio company (8) · BioMarin Pharmaceutical (5) · Sanofi (2) · Children's Hospitals and Clinics of Minnesota (1) · Christopher Dvorak (1) · Pfizer (1)
What is being tested here
Drugs under test in Osteochondrodysplasias studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Infigratinib | 3 | 2 | 5 |
| Vosoritide | 0 | 3 | 4 |
| Recifercept | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Jan 2027An Interventional Study of Infigratinib in Children With Hypochondroplasia · Phase 3 · QED Therapeutics, a BridgeBio company
Who these studies take
Of the 3 Osteochondrodysplasias studies recruiting now, 0 (0%) set no upper age limit and 3 (100%) stop at 75 or younger. 3 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (67%) | 2 (67%) |
| 18 | 0 (0%) | 0 (0%) |
| 30 | 0 (0%) | 0 (0%) |
| 40 | 0 (0%) | 0 (0%) |
| 50 | 0 (0%) | 0 (0%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 18 studies, recruiting or not: 94% stop at 75 or younger and 94% at 65; 94% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 18 of 18. search them.
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationNCT05145010Phase 210 countries
- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaRecruitingNCT07441876Phase 2/39 countries
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT07393373Phase 210 countries
- An Interventional Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT06873035Phase 2/310 countries
- Prospective Clinical Assessment Study in Children With HypochondroplasiaRecruitingNCT0641097610 countries
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)RecruitingNCT07169279Phase 27 countries
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With AchondroplasiaTerminatedNCT06067425Phase 25 countries
- Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)CompletedNCT0403581111 countries
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaCompletedNCT06164951Phase 310 countries
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaActive, not recruitingNCT03424018Phase 37 countries
- Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaActive, not recruitingNCT06455059Phase 39 countries
- Study of Infigratinib in Children With AchondroplasiaCompletedNCT04265651Phase 26 countries
- A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults SubjectsCompletedNCT05846009Phase 11 country
- A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With AchondroplasiaCompletedNCT03583697Phase 24 countries
- Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in AchondroplasiaTerminatedNCT05116046Phase 27 countries
- A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaCompletedNCT03197766Phase 37 countries
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT012000171 country
- Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip DiseaseCompletedNCT017074331 country